Within the Radiopharmaceutical Theranostics Market , the market is segmented by application, radioisotope, and end-user, revealing a dynamic landscape with distinct growth drivers. According to the MRFR report, by application, oncology is the largest segment, holding a significant share due to the increasing incidence of cancer globally. This segment is driven by the rising demand for targeted therapy options that improve treatment outcomes and reduce side effects. Theranostic agents are extensively used in the management of neuroendocrine tumors (NETs) and prostate cancer, with blockbuster drugs like Lutathera and Pluvicto leading the way.

While oncology leads, cardiology is emerging as the fastest-growing segment. This growth is spurred by advancements in radiopharmaceuticals that aid in the diagnosis and treatment of heart diseases. Healthcare providers are increasingly adopting these innovative solutions to enhance patient care. The rising prevalence of cardiovascular diseases and the need for precise diagnostic tools are driving the rapid uptake of theranostic approaches in cardiology. Neurology is also emerging as a promising segment, fueled by a growing interest in diagnosing and treating neurological disorders with theranostic approaches. The introduction of advanced imaging agents is assisting in conditions like Alzheimer's and epilepsy, where traditional diagnostic methods often fall short.

By radioisotope, Fluorine-18 (18F) holds the largest market share, renowned for its critical role in PET imaging for oncology. Its widespread availability and established clinical utility make it the dominant isotope. However, Gallium-68 (68Ga) is the fastest-growing segment. The increasing adoption of Ga-68 labeled tracers for PET imaging in neuroendocrine tumors and prostate cancer is driving its growth. Lutetium-177 (Lu-177) holds the largest market share in the therapeutic segment, driven by its use in Pluvicto and Lutathera. The development of novel alpha-emitters, such as Actinium-225 (Ac-225) and Lead-212 (Pb-212), represents the next frontier, offering the potential for even more potent therapies.

By end-user, hospitals captured the largest revenue share of the radiopharmaceutical theranostics market. Hospitals are the primary settings for the administration of these complex therapies, as they have the necessary infrastructure, trained personnel, and regulatory compliance. However, diagnostic imaging centers and specialized cancer centers are the fastest-growing segments. The shift towards outpatient care and the establishment of dedicated theranostic centers are driving this growth.

By modality, PET/CT holds the largest share, driven by its superior sensitivity and quantitative capabilities. SPECT/CT is also a significant modality, widely used for imaging with Tc-99m and Lu-177. The integration of PET and SPECT with CT provides anatomical localization, improving diagnostic accuracy and treatment planning. As theranostics continues to evolve, the demand for hybrid imaging systems is expected to grow, further shaping the segmentation of the market.